Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 19, 2017--
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.
Siegall, Ph.D., President and Chief Executive Officer, will present at
the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8,
2018 at 10:30 a.m. Pacific Time. Both the presentation and question and
answer session that follows at 11:00 a.m. will be webcast live and
available for replay from Seattle Genetics’ website at www.seattlegenetics.com
in the Investors section.
About Seattle Genetics
Seattle Genetics is an innovative biotechnology company dedicated to
improving the lives of people with cancer through novel antibody-based
therapies. The company’s industry-leading antibody-drug conjugate (ADC)
technology harnesses the targeting ability of antibodies to deliver
cell-killing agents directly to cancer cells. Seattle Genetics
commercializes ADCETRIS® (brentuximab vedotin) for the treatment of
several types of CD30-expressing lymphomas. The company is also
advancing a robust pipeline of novel therapies for solid tumors and
blood-related cancers designed to address significant unmet medical
needs and improve treatment outcomes for patients. More information can
be found at www.seattlegenetics.com
and follow @SeattleGenetics on Twitter.